377 related articles for article (PubMed ID: 38339003)
1. Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma.
Farah C; Mignion L; Jordan BF
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38339003
[TBL] [Abstract][Full Text] [Related]
2. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Luke JJ
Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
[TBL] [Abstract][Full Text] [Related]
5. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
Mandalà M; Massi D
Handb Exp Pharmacol; 2018; 249():129-143. PubMed ID: 28238077
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
7. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.
Naderi-Azad S; Sullivan R
Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263
[No Abstract] [Full Text] [Related]
8. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns and overall survival in
Atkins MB; Julian C; Secrest MH; Lee J; Abajo-Guijarro AM; McKenna E
Future Oncol; 2022 Jun; 18(18):2233-2245. PubMed ID: 35441522
[TBL] [Abstract][Full Text] [Related]
10. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
11. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.
Ferrucci PF; Lens M; Cocorocchio E
Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635
[TBL] [Abstract][Full Text] [Related]
12. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.
Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D
JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096
[TBL] [Abstract][Full Text] [Related]
13. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
14. Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.
Ziogas DC; Konstantinou F; Bouros S; Gogas H
Expert Rev Anticancer Ther; 2020 Jan; 20(1):53-62. PubMed ID: 31903803
[No Abstract] [Full Text] [Related]
15. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
Babacan NA; Eroglu Z
Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
[TBL] [Abstract][Full Text] [Related]
19. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
20. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Haist M; Stege H; Kuske M; Bauer J; Klumpp A; Grabbe S; Bros M
Cancer Metastasis Rev; 2023 Jun; 42(2):481-505. PubMed ID: 37022618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
